

# Supporting Information For:

## Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones

M. Shaheer Malik <sup>1,\*†</sup>, Shaikh Faazil <sup>2,3,†</sup>, Meshari A. Alsharif <sup>1</sup>, Qazi Mohammad Sajid Jamal <sup>4</sup>, Jabir H. Al-Fahemi <sup>1</sup>, Amrita Banerjee <sup>5,6</sup>, Arpita Chattopadhyay <sup>7</sup>, Samir Kumar Pal <sup>8</sup>, Ahmed Kamal <sup>3,9,\*</sup> and Saleh A. Ahmed <sup>1,10,\*</sup>

<sup>1</sup> Department of Chemistry, Faculty of Applied Sciences, Umm Al-Qura University, Makkah 21955, Saudi Arabia; maasharif@uqu.edu.sa (M.A.A.)

<sup>2</sup> Department of Chemistry, Poona College of Arts, Science and Commerce, Pune 411001, India

<sup>3</sup> Department of Medicinal Chemistry and Pharmacology, CSIR—Indian Institute of Chemical Technology, Hyderabad 500007, India

<sup>4</sup> Department of Health Informatics, College of Public Health and Health Informatics, Qassim University, Al Bukayriyah 52741, Saudi Arabia; m.quazi@qu.edu.sa

<sup>5</sup> Department of Physics, Jadavpur University, 188, Raja S.C. Mallick Rd., Kolkata 700032, India; amritabanerjee30@gmail.com

<sup>6</sup> Technical Research Centre, S. N. Bose National Centre for Basic Sciences, Block JD, Sector III, Salt Lake, Kolkata 700106, India

<sup>7</sup> Department of Basic Science and Humanities, Techno International New Town, Block—DG 1/1, Action Area 1, New Town, Rajarhat, Kolkata 700156, India; arpita.chattopadhyay@gmail.com

<sup>8</sup> Department of Chemical and Biological Sciences, S. N. Bose National Centre for Basic Sciences, Block JD, Sector 3, Salt Lake, Kolkata 700106, India; skpal@bose.res.in

<sup>9</sup> Department of Pharmacy, Birla Institute of Technology and Science-Pilani, Hyderabad 500078, India

<sup>10</sup> Chemistry Department, Faculty of Science, Assiut University, Assiut 71516, Egypt

\* Correspondence: msmalik@uqu.edu.sa (M.S.M.); ahmedkamal@iict.res.in (A.K.); saahmed@uqu.edu.sa (S.A.A.)

† These authors contributed equally to this work.

**Keywords:** Oxazolidinone, Linezolid, antibacterial, molecular modeling, molecular dynamics, ADME properties

### Contents:

- **Table S1:** Physicochemical properties of compounds **2**, **3a-j**, **4a-j** and linezolid (control)
- **Table S2:** Lipophilicity and water solubility of compounds **2**, **3a-j**, **4a-j** and linezolid (control)
- **Table S3:** Some other water solubility parameters of compounds **2**, **3a-j**, **4a-j** and linezolid (control)
- **Table S4:** Pharmacokinetics parameters of compounds **2**, **3a-j**, **4a-j** and linezolid (control)
- **Table S5:** Drug likeness and medicinal chemistry of compounds **2**, **3a-j**, **4a-j** and linezolid (control)
- **Table S6:** Toxicity of compounds **2**, **3a-j**, **4a-j** and linezolid (control)

**Table S1.** Physicochemical properties of compounds **2**, **3a-j**, **4a-j** and linezolid (control).

Molecule	#Heavy atoms	#Aromatic heavy atoms	Fraction Csp <sup>3</sup>	#Rotatable bonds	#H-bond acceptors	#H-bond donors	MR	TPSA
2	38	11	0.46	10	9	1	143.52	150.38
3a	35	11	0.4	8	10	1	131.55	166.6
3b	41	17	0.31	9	10	1	155.36	166.6
3c	43	17	0.3	10	11	1	160.58	183.67
3d	44	17	0.31	10	13	1	155.39	166.6
3e	42	17	0.31	10	11	1	156.88	175.83
3f	41	17	0.28	9	10	1	155.4	166.6
3g	41	17	0.28	9	11	1	150.35	166.6
3h	42	17	0.28	9	12	1	150.31	166.6
3i	42	17	0.28	9	12	1	150.31	166.6
3j	44	21	0.25	9	11	1	165.69	179.49
4a	37	18	0.24	8	4	1	152.46	87.18
4b	32	15	0.3	6	5	1	127.24	100.32
4c	29	12	0.37	6	6	1	113.06	112.96
4d	34	15	0.33	6	4	1	142.83	115.42
4e	37	17	0.26	8	5	1	149.89	100.32
4f	36	6	0.62	9	6	1	149.63	119.96
4g	43	6	0.66	12	8	1	174.6	124.2
4h	36	12	0.46	9	8	1	138.02	117.2
4i	40	15	0.41	9	6	2	159.26	107.21
4j	37	12	0.44	9	7	1	145.24	104.31
Linezolid	24	6	0.5	5	5	1	91.06	71.11

**Table S2.** Lipophilicity and water solubility of compounds **2**, **3a-j**, **4a-j** and linezolid (control).

Molecule	iLOGP	XLOGP3	WLOGP	MLOGP	Silicos-IT Log P	Consensus Log P	ESOL Log S	ESOL Solubility (mg/ml)	ESOL Solubility (mol/l)
2	3.53	2.94	2.42	1.67	-0.48	2.02	-4.55	1.49E-02	2.79E-05
3a	2.45	1.34	1.52	0.34	-1.99	0.73	-3.56	1.41E-01	2.75E-04
3b	3.4	3.27	3.26	1.39	-0.46	2.17	-5.26	3.26E-03	5.55E-06
3c	2.74	2.58	3.15	0.78	-0.5	1.75	-4.91	7.49E-03	1.22E-05
3d	3.08	3.78	5.12	1.69	0.12	2.76	-5.82	9.60E-04	1.50E-06
3e	3.2	2.87	2.96	0.92	-0.91	1.81	-5.03	5.64E-03	9.34E-06
3f	3.34	3.53	3.61	1.66	-0.34	2.36	-5.55	1.73E-03	2.84E-06
3g	2.77	3	3.51	1.56	-0.56	2.06	-5.11	4.59E-03	7.76E-06
3h	2.83	3.1	4.07	1.93	-0.13	2.36	-5.28	3.22E-03	5.28E-06
3i	3.04	3.1	4.07	1.93	-0.13	2.4	-5.28	3.22E-03	5.28E-06
3j	2.81	3.17	3.5	1.14	-0.57	2.01	-5.47	2.12E-03	3.40E-06
4a	4.18	5.21	4.61	4.04	4.71	4.55	-6.16	3.55E-04	6.86E-07
4b	3.22	3.55	3.54	2.71	3.23	3.25	-4.85	6.41E-03	1.41E-05
4c	2.53	1.34	1.58	0.93	1.73	1.62	-3.18	2.74E-01	6.57E-04
4d	4.2	5.49	4.97	4.2	5.64	4.9	-6.45	1.83E-04	3.52E-07
4e	4.32	4.96	5	3.35	5.02	4.53	-6.14	3.95E-04	7.29E-07
4f	3.46	2.16	1.86	2.39	1.17	2.21	-3.98	5.53E-02	1.06E-04
4g	5.33	2.39	1.99	2.26	0.66	2.53	-4.42	2.32E-02	3.82E-05
4h	3.27	1.57	1.71	0.85	1.13	1.71	-3.59	1.30E-01	2.60E-04
4i	4.02	4.21	3.71	2.73	3.33	3.6	-5.6	1.40E-03	2.54E-06
4j	3.25	3.27	2.96	2.29	2.35	2.82	-4.86	7.43E-03	1.39E-05
Linezolid	2.58	0.69	0.78	0.99	1.25	1.26	-2.22	2.03E+00	6.01E-03

**Table S3.** Some other water solubility parameters of compounds **2**, **3a-j**, **4a-j** and linezolid (control).

Molecule	ESOL Class	Ali Log S	Ali Solubility (mg/ml)	Ali Solubility (mol/l)	Ali Class	Silicos-IT LogSw	Silicos-IT Solubility (mg/ml)	Silicos-IT Solubility (mol/l)	Silicos-IT class
<b>2</b>	Moderately soluble	-5.76	9.27E-04	1.74E-06	Moderately soluble	-4.22	3.21E-02	6.01E-05	Moderately soluble
<b>3a</b>	Soluble	-4.44	1.86E-02	3.63E-05	Moderately soluble	-3.66	1.12E-01	2.18E-04	Soluble
<b>3b</b>	Moderately soluble	-6.44	2.12E-04	3.61E-07	Poorly soluble	-6.08	4.85E-04	8.26E-07	Poorly soluble
<b>3c</b>	Moderately soluble	-6.09	5.06E-04	8.21E-07	Poorly soluble	-5.99	6.24E-04	1.01E-06	Moderately soluble
<b>3d</b>	Moderately soluble	-6.97	6.84E-05	1.07E-07	Poorly soluble	-6.51	1.99E-04	3.10E-07	Poorly soluble
<b>3e</b>	Moderately soluble	-6.22	3.62E-04	6.00E-07	Poorly soluble	-5.8	9.52E-04	1.58E-06	Moderately soluble
<b>3f</b>	Moderately soluble	-6.71	1.18E-04	1.94E-07	Poorly soluble	-6.29	3.15E-04	5.19E-07	Poorly soluble
<b>3g</b>	Moderately soluble	-6.16	4.07E-04	6.87E-07	Poorly soluble	-5.97	6.34E-04	1.07E-06	Moderately soluble
<b>3h</b>	Moderately soluble	-6.27	3.30E-04	5.41E-07	Poorly soluble	-6.22	3.63E-04	5.96E-07	Poorly soluble
<b>3i</b>	Moderately soluble	-6.27	3.30E-04	5.41E-07	Poorly soluble	-6.22	3.63E-04	5.96E-07	Poorly soluble
<b>3j</b>	Moderately soluble	-6.61	1.53E-04	2.45E-07	Poorly soluble	-6.95	7.02E-05	1.12E-07	Poorly soluble
<b>4a</b>	Poorly soluble	-6.79	8.43E-05	1.63E-07	Poorly soluble	-8.13	3.85E-06	7.45E-09	Poorly soluble
<b>4b</b>	Moderately soluble	-5.34	2.07E-03	4.55E-06	Moderately soluble	-6.48	1.51E-04	3.32E-07	Poorly soluble
<b>4c</b>	Soluble	-3.31	2.03E-01	4.85E-04	Soluble	-4.88	5.48E-03	1.31E-05	Moderately soluble
<b>4d</b>	Poorly soluble	-7.67	1.11E-05	2.13E-08	Poorly soluble	-7.47	1.77E-05	3.41E-08	Poorly soluble
<b>4e</b>	Poorly soluble	-6.8	8.49E-05	1.57E-07	Poorly soluble	-7.93	6.38E-06	1.18E-08	Poorly soluble
<b>4f</b>	Soluble	-4.31	2.55E-02	4.88E-05	Moderately soluble	-3.68	1.10E-01	2.09E-04	Soluble
<b>4g</b>	Moderately soluble	-4.64	1.39E-02	2.29E-05	Moderately soluble	-3.7	1.21E-01	2.00E-04	Soluble
<b>4h</b>	Soluble	-3.64	1.14E-01	2.28E-04	Soluble	-4.92	5.99E-03	1.20E-05	Moderately soluble
<b>4i</b>	Moderately soluble	-6.17	3.72E-04	6.74E-07	Poorly soluble	-6.88	7.29E-05	1.32E-07	Poorly soluble
<b>4j</b>	Moderately soluble	-5.13	3.91E-03	7.33E-06	Moderately soluble	-5.87	7.19E-04	1.35E-06	Moderately soluble
Linezolid	Soluble	-1.76	5.86E+00	1.74E-02	Very soluble	-3.19	2.18E-01	6.47E-04	Soluble

**Table S4.** Pharmacokinetics parameters of compounds **2**, **3a-j**, **4a-j** and linezolid (control).

Molecule	GI absorption	BBB permeant	Pgp substrate	CYP1A2 inhibitor	CYP2C19 inhibitor	CYP2C9 inhibitor	CYP2D6 inhibitor	CYP3A4 inhibitor	-log Kp (cm/s)
<b>2</b>	Low	No	Yes	No	Yes	Yes	No	Yes	-7.47
<b>3a</b>	Low	No	Yes	No	Yes	Yes	No	Yes	-8.47
<b>3b</b>	Low	No	Yes	No	No	Yes	No	Yes	-7.56
<b>3c</b>	Low	No	Yes	No	No	Yes	No	Yes	-8.22
<b>3d</b>	Low	No	Yes	No	No	Yes	No	Yes	-7.53
<b>3e</b>	Low	No	Yes	No	No	Yes	No	Yes	-7.94
<b>3f</b>	Low	No	Yes	No	No	Yes	No	Yes	-7.5
<b>3g</b>	Low	No	Yes	No	No	Yes	No	Yes	-7.78
<b>3h</b>	Low	No	Yes	No	No	Yes	No	Yes	-7.82
<b>3i</b>	Low	No	Yes	No	No	Yes	No	Yes	-7.82
<b>3j</b>	Low	No	Yes	No	No	Yes	No	Yes	-7.86
<b>4a</b>	High	No	Yes	No	Yes	Yes	Yes	Yes	-5.76
<b>4b</b>	High	No	Yes	Yes	Yes	Yes	Yes	Yes	-6.56
<b>4c</b>	High	No	Yes	No	Yes	No	Yes	Yes	-7.9
<b>4d</b>	Low	No	Yes	Yes	Yes	Yes	Yes	Yes	-5.57
<b>4e</b>	High	No	Yes	No	Yes	Yes	Yes	Yes	-6.08
<b>4f</b>	High	No	Yes	No	Yes	No	Yes	Yes	-7.96
<b>4g</b>	High	No	Yes	No	Yes	Yes	Yes	Yes	-8.3
<b>4h</b>	High	No	Yes	No	Yes	Yes	No	Yes	-8.24
<b>4i</b>	High	No	Yes	No	Yes	Yes	Yes	Yes	-6.68
<b>4j</b>	High	No	Yes	No	Yes	Yes	Yes	Yes	-7.24
Linezolid	High	No	Yes	No	No	No	No	No	-7.87

**Table S5.** Drug likeness and medicinal chemistry of compounds **2**, **3a-j**, **4a-j** and linezolid (control).

Molecule	Lipinski #violations	Ghose #violations	Veber #violations	Egan #violations	Muegge #violations	Bioavailability Score	PAINS #alerts	Brenk #alerts	Leadlikeness #violations	Synthetic accessibility
<b>2</b>	2	2	1	1	1	0.17	1	3	2	4.57
<b>3a</b>	2	2	1	1	1	0.17	1	2	2	4.22
<b>3b</b>	2	2	1	1	1	0.17	1	2	2	4.63
<b>3c</b>	2	2	1	1	3	0.17	1	2	2	4.69
<b>3d</b>	2	2	1	1	3	0.17	1	2	3	4.63
<b>3e</b>	2	2	1	1	3	0.17	1	2	2	4.63
<b>3f</b>	2	2	1	1	2	0.17	1	2	3	4.51
<b>3g</b>	2	2	1	1	2	0.17	1	2	2	4.53
<b>3h</b>	2	2	1	1	3	0.17	1	2	2	4.56
<b>3i</b>	2	2	1	1	3	0.17	1	2	2	4.54

3j	2	2	1	1	3	0.17	1	2	2	4.72
4a	1	2	0	0	1	0.55	1	2	3	4.31
4b	0	0	0	0	0	0.55	1	0	2	3.99
4c	0	0	0	0	0	0.55	1	0	1	3.59
4d	2	2	0	0	1	0.17	1	0	2	4.1
4e	1	2	0	0	0	0.55	1	1	3	4.52
4f	1	2	0	0	0	0.55	1	1	2	4.58
4g	2	3	1	0	1	0.17	1	1	2	5.19
4h	2	2	0	0	0	0.17	1	1	2	4.22
4i	1	3	0	0	0	0.55	1	1	3	4.46
4j	1	2	0	0	0	0.55	1	2	2	4.19
Linezolid	0	0	0	0	0	0.55	1	0	0	3.32

**Table S6.** Toxicity of compounds **2**, **3a-j**, **4a-j** and linezolid (control).

Molecule	hERG Blockers	Human Hepatotoxicity	Drug induced liver injury	Ames Toxicity	Rat Oral Acute Toxicity	FDA Maximum Daily Dose	Skin Sensitization	Carcinogenicity	Eye Corrosion	Eye Irritation	Respiratory Toxicity
2	0.43	0.993	0.982	0.995	0.493	0.249	0.457	0.975	0.003	0.008	0.029
3a	0.719	0.993	0.985	0.998	0.371	0.44	0.331	0.968	0.003	0.007	0.187
3b	0.817	0.992	0.99	0.998	0.282	0.208	0.18	0.963	0.003	0.007	0.146
3c	0.85	0.993	0.992	0.998	0.287	0.216	0.153	0.966	0.003	0.007	0.094
3d	0.757	0.994	0.988	0.993	0.363	0.88	0.181	0.949	0.003	0.006	0.341
3e	0.855	0.994	0.99	0.998	0.264	0.189	0.157	0.961	0.003	0.007	0.155
3f	0.844	0.991	0.99	0.998	0.36	0.175	0.176	0.962	0.003	0.007	0.145
3g	0.806	0.996	0.99	0.998	0.26	0.233	0.148	0.965	0.003	0.007	0.205
3h	0.64	0.995	0.988	0.997	0.145	0.44	0.166	0.968	0.003	0.007	0.263
3i	0.69	0.998	0.989	0.998	0.154	0.394	0.152	0.969	0.003	0.006	0.318
3j	0.741	0.992	0.991	0.998	0.321	0.236	0.172	0.956	0.003	0.007	0.15
4a	0.409	0.98	0.986	0.619	0.05	0.962	0.281	0.517	0.003	0.009	0.327
4b	0.299	0.982	0.969	0.938	0.676	0.758	0.411	0.911	0.003	0.01	0.197
4c	0.568	0.984	0.985	0.819	0.055	0.8	0.468	0.575	0.003	0.01	0.072
4d	0.138	0.99	0.974	0.93	0.053	0.907	0.814	0.942	0.003	0.011	0.27
4e	0.458	0.972	0.979	0.943	0.202	0.527	0.664	0.901	0.003	0.011	0.347
4f	0.135	0.992	0.959	0.66	0.219	0.307	0.304	0.937	0.003	0.007	0.016
4g	0.084	0.997	0.939	0.348	0.287	0.177	0.234	0.956	0.003	0.005	0.004
4h	0.476	0.993	0.983	0.249	0.077	0.365	0.586	0.759	0.003	0.007	0.035
4i	0.505	0.993	0.946	0.692	0.529	0.841	0.194	0.894	0.003	0.008	0.06
4j	0.427	0.995	0.97	0.754	0.327	0.503	0.209	0.916	0.003	0.007	0.039
Linezolid	0.029	0.971	0.918	0.676	0.042	0.373	0.577	0.725	0.003	0.011	0.046